SLN Silence Therapeutics plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1479615
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-98.2%
TTM net income YoY20.3%
TTM EPS YoY22.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin95.0%
Operating margin-12,343.6%
Net margin-11,276.5%
FCF margin-9,681.6%
EBITDA margin-12,279.2%
Returns
ROE-35.6%
ROA-24.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.6%
Debt / equity0.00x
Current ratio23.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $559,000 | $43.26M |
| Cost of revenue | $215,000 | $11.81M |
| Gross profit | $344,000 | $31.45M |
| R&D expense | $67.75M | $67.88M |
| SG&A expense | $22.34M | $26.88M |
| Operating income | -$91.08M | -$63.32M |
| Pretax income | -$88.60M | -$44.46M |
| Income tax | $11,000 | $845,000 |
| Net income | -$88.61M | -$45.31M |
| EBITDA | -$90.77M | -$62.98M |
| EPS (basic) | -0.63 | -0.33 |
| EPS (diluted) | -0.63 | -0.33 |
| Weighted avg. shares (diluted) | 141.69M | 138.75M |
| Balance sheet | ||
| Cash & equivalents | $11.28M | $121.33M |
| Short-term investments | $73.84M | $26.00M |
| Receivables | $0 | $972,000 |
| Current assets | $118.66M | $187.37M |
| PP&E, net | $1.58M | $1.82M |
| Goodwill | $10.62M | $9.39M |
| Intangibles | $288,000 | $312,000 |
| Total assets | $131.44M | $202.63M |
| Current liabilities | $13.61M | $16.82M |
| Total liabilities | $69.14M | $68.61M |
| Shareholders' equity | $62.30M | $134.02M |
| Shares outstanding | 141.70M | 141.67M |
| Cash flow statement | ||
| Operating cash flow | -$62.27M | -$67.64M |
| Capital expenditure | $55,000 | $211,000 |
| Free cash flow | -$62.33M | -$67.85M |
| Investing cash flow | -$47.99M | -$21.97M |
| Financing cash flow | $15,000 | $142.09M |
| Depreciation & amortization | $312,000 | $336,000 |
| Stock-based compensation | $8.07M | $16.31M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.